Clinical guidelines for interstitial cystitis/bladder pain syndrome.
Hunner lesions
bladder pain syndrome
guidelines
hypersensitive bladder symptoms
interstitial cystitis
Journal
International journal of urology : official journal of the Japanese Urological Association
ISSN: 1442-2042
Titre abrégé: Int J Urol
Pays: Australia
ID NLM: 9440237
Informations de publication
Date de publication:
Jul 2020
Jul 2020
Historique:
received:
15
01
2020
accepted:
27
02
2020
pubmed:
16
4
2020
medline:
28
4
2021
entrez:
16
4
2020
Statut:
ppublish
Résumé
The clinical guidelines for interstitial cystitis and related symptomatic conditions were revised by updating our previous guidelines. The current guidelines define interstitial cystitis/bladder pain syndrome as a condition with chronic pelvic pain, pressure or discomfort perceived to be related to the urinary bladder accompanied by other urinary symptoms, such as persistent urge to void or urinary frequency in the absence of confusable diseases. The characteristic symptom complex is collectively referred as hypersensitive bladder symptoms. Interstitial cystitis/bladder pain syndrome is divided into Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis and bladder pain syndrome represent interstitial cystitis/bladder pain syndrome with Hunner lesions and interstitial cystitis/bladder pain syndrome without Hunner lesions, respectively. So-called non-Hunner-type interstitial cystitis featured by glomerulations or bladder bleeding after distension is included in bladder pain syndrome. The symptoms are virtually indistinguishable between Hunner-type interstitial cystitis and bladder pain syndrome; however, Hunner-type interstitial cystitis and bladder pain syndrome should be considered as a separate entity of disorder. Histopathology totally differs between Hunner-type interstitial cystitis and bladder pain syndrome; Hunner-type interstitial cystitis is associated with severe inflammation of the urinary bladder accompanied by lymphoplasmacytic infiltration and urothelial denudation, whereas bladder pain syndrome shows little pathological changes in the bladder. Pathophysiology would also differ between Hunner-type interstitial cystitis and bladder pain syndrome, involving interaction of multiple factors, such as inflammation, autoimmunity, infection, exogenous substances, urothelial dysfunction, neural hyperactivity and extrabladder disorders. The patients should be treated differently based on the diagnosis of Hunner-type interstitial cystitis or bladder pain syndrome, which requires cystoscopy to determine the presence or absence Hunner lesions. Clinical studies are to be designed to analyze outcomes separately for Hunner-type interstitial cystitis and bladder pain syndrome.
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
578-589Commentaires et corrections
Type : CommentIn
Informations de copyright
© 2020 The Japanese Urological Association.
Références
Homma Y, Ueda T, Tomoe H et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder syndrome. Int. J. Urol. 2009; 16: 597-615.
Homma Y, Ueda T, Tomoe H et al. Clinical guidelines for interstitial cystitis and hypersensitive bladder updated in 2015. Int. J. Urol. 2016; 23: 542-9.
Homma Y. Interstitial cystitis, bladder pain syndrome, hypersensitive bladder, and interstitial cystitis/bladder pain syndrome - clarification of definitions and relationships. Int. J. Urol. 2019; 26(Suppl 1): 20-4.
van de Merwe JP, Nordling J, Bouchelouche P et al. Diagnostic criteria, classification, and nomenclature for painful bladder syndrome/interstitial cystitis: an ESSIC proposal. Eur. Urol. 2008; 53: 60-7.
Hanno PM, Burks DA, Clemens JQ et al. AUA guideline for the diagnosis and treatment of interstitial cystitis/bladder pain syndrome. J. Urol. 2011; 185: 2162-70.
Hanno PM, Erickson D, Moldwin R, Faraday MM, American Urological A. Diagnosis and treatment of interstitial cystitis/bladder pain syndrome: AUA guideline amendment. J. Urol. 2015; 193: 1545-53.
Homma Y. Hypersensitive bladder: a solution to confused terminology and ignorance concerning interstitial cystitis. Int. J. Urol. 2014; 21(Suppl 1): 43-7.
Akiyama Y, Maeda D, Katoh H et al. Molecular taxonomy of interstitial cystitis/bladder pain syndrome based on whole transcriptome profiling by next-generation RNA sequencing of bladder mucosal biopsies. J. Urol. 2019; 202: 290-300.
Akiyama Y, Homma Y, Maeda D. Pathology and terminology of interstitial cystitis/bladder pain syndrome: a review. Histol. Histopathol. 2019; 34: 25-32.
Wennevik GE, Meijlink JM, Hanno P, Nordling J. The role of glomerulations in bladder pain syndrome: a review. J. Urol. 2016; 195: 19-25.
Lee MH, Chang KM, Tsai WC. Morbidity rate and medical utilization in interstitial cystitis/painful bladder syndrome. Int. Urogynecol. J. 2018; 29: 1045-50.
Messing EM, Stamey TA. Interstitial cystitis: early diagnosis, pathology, and treatment. Urology 1978; 12: 381-92.
Mattila J. Vascular immunopathology in interstitial cystitis. Clin. Immunol. Immunopathol. 1982; 23: 648-55.
Lynes WL, Flynn SD, Shortliffe LD, Stamey TA. The histology of interstitial cystitis. Am. J. Surg. Pathol. 1990; 14: 969-76.
Gillespie L, Said J, Sostrin S, Kleiwer K. Immunofluorescent and histochemical staining confirm the identification of the many diseases called interstitial cystitis. Br. J. Urol. 1990; 66: 265-73.
Maeda D, Akiyama Y, Morikawa T et al. Hunner-type (classic) interstitial cystitis: a distinct inflammatory disorder characterized by pancystitis, with frequent expansion of clonal B-cells and epithelial denudation. PLoS One 2015; 10: e0143316.
Johansson SL, Fall M. Clinical features and spectrum of light microscopic changes in interstitial cystitis. J. Urol. 1990; 143: 1118-24.
Christmas TJ, Rode J. Characteristics of mast cells in normal bladder, bacterial cystitis and interstitial cystitis. Br. J. Urol. 1991; 68: 473-8.
Theoharides TC, Sant GR, El-Mansoury M, Letourneau R, Ucci AA, Meares EM. Activation of bladder mast cells in interstitial cystitis: a light and electron microscopic study. J. Urol. 1995; 153: 629-36.
Dundore PA, Schwartz AM, Semerjian H. Mast cell counts are not useful in the diagnosis of nonulcerative interstitial cystitis. J. Urol. 1996; 155: 885-7.
Peeker R, Enerback L, Fall M, Aldenborg F. Recruitment, distribution and phenotypes of mast cells in interstitial cystitis. J. Urol. 2000; 163: 1009-15.
Yamada T, Murayama T, Mita H, Akiyama K. Subtypes of bladder mast cells in interstitial cystitis. Int. J. Urol. 2000; 7: 292-7.
Gamper M, Regauer S, Welter J, Eberhard J, Viereck V. Are mast cells still good biomarkers for bladder pain syndrome/interstitial cystitis? J. Urol. 2015; 193: 1994-2000.
Akiyama Y, Maeda D, Morikawa T et al. Digital quantitative analysis of mast cell infiltration in interstitial cystitis. Neurourol. Urodyn. 2018; 37: 650-7.
Theoharides TC, Cochrane DE. Critical role of mast cells in inflammatory diseases and the effect of acute stress. J. Neuroimmunol. 2004; 146: 1-12.
Yoshimura N, Oguchi T, Yokoyama H et al. Bladder afferent hyperexcitability in bladder pain syndrome/interstitial cystitis. Int. J. Urol. 2014; 21(Suppl 1): 18-25.
Logadottir Y, Delbro D, Fall M et al. Cytokine expression in patients with bladder pain syndrome/interstitial cystitis ESSIC type 3C. J. Urol. 2014; 192: 1564-8.
Colaco M, Koslov DS, Keys T et al. Correlation of gene expression with bladder capacity in interstitial cystitis/bladder pain syndrome. J. Urol. 2014; 192: 1123-9.
Homma Y, Nomiya A, Tagaya M et al. Increased mRNA expression of genes involved in pronociceptive inflammatory reactions in bladder tissue of interstitial cystitis. J. Urol. 2013; 190: 1925-31.
Kim SW, Im YJ, Choi HC, Kang HJ, Kim JY, Kim JH. Urinary nerve growth factor correlates with the severity of urgency and pain. Int. Urogynecol. J. 2014; 25: 1561-7.
Tyagi P, Killinger K, Tyagi V, Nirmal J, Chancellor M, Peters KM. Urinary chemokines as noninvasive predictors of ulcerative interstitial cystitis. J. Urol. 2012; 187: 2243-8.
Jiang YH, Peng CH, Liu HT, Kuo HC. Increased pro-inflammatory cytokines, C-reactive protein and nerve growth factor expressions in serum of patients with interstitial cystitis/bladder pain syndrome. PLoS One 2013; 8: e76779.
Niimi A, Igawa Y, Aizawa N et al. Diagnostic value of urinary CXCL10 as a biomarker for predicting Hunner type interstitial cystitis. Neurourol. Urodyn. 2018; 37: 1113-9.
Gamper M, Viereck V, Eberhard J et al. Local immune response in bladder pain syndrome/interstitial cystitis ESSIC type 3C. Int. Urogynecol. J. 2013; 24: 2049-57.
Anand P, Singh B, Jaggi AS, Singh N. Mast cells: an expanding pathophysiological role from allergy to other disorders. Naunyn-Schmiedeberg's Arch. Pharmacol. 2012; 385: 657-70.
Kim A, Han JY, Ryu CM et al. Histopathological characteristics of interstitial cystitis/bladder pain syndrome without Hunner lesion. Histopathology 2017; 71: 415-24.
Yu L, Wang L, Chen S. Endogenous toll-like receptor ligands and their biological significance. J. Cell. Mol. Med. 2010; 14: 2592-603.
Altuntas CZ, Daneshgari F, Sakalar C et al. Autoimmunity to uroplakin II causes cystitis in mice: a novel model of interstitial cystitis. Eur. Urol. 2012; 61: 193-200.
Abernethy MG, Rosenfeld A, White JR, Mueller MG, Lewicky-Gaupp C, Kenton K. Urinary microbiome and cytokine levels in women with interstitial cystitis. Obstet. Gynecol. 2017; 129: 500-6.
Siddiqui H, Lagesen K, Nederbragt AJ, Jeansson SL, Jakobsen KS. Alterations of microbiota in urine from women with interstitial cystitis. BMC Microbiol. 2012; 12: 205.
Jhang JF, Hsu YH, Peng CW, Jiang YH, Ho HC, Kuo HC. Epstein-Barr virus as a potential etiology of persistent bladder inflammation in human interstitial cystitis/bladder pain syndrome. J. Urol. 2018; 200: 590-6.
Minamitani T, Yasui T, Ma Y et al. Evasion of affinity-based selection in germinal centers by Epstein-Barr virus LMP2A. Proc. Natl. Acad. Sci. USA 2015; 112: 11612-7.
Manfredo Vieira S, Hiltensperger M, Kumar V et al. Translocation of a gut pathobiont drives autoimmunity in mice and humans. Science 2018; 359: 1156-61.
Bassaly R, Downes K, Hart S. Dietary consumption triggers in interstitial cystitis/bladder pain syndrome patients. Female Pelvic Med. Reconstr. Surg. 2011; 17: 36-9.
Sutcliffe S, Bradley CS, Clemens JQ et al. Urological chronic pelvic pain syndrome flares and their impact: qualitative analysis in the MAPP network. Int. Urogynecol. J. 2015; 26: 1047-60.
Ueda T, Yoshida T, Tanoue H et al. Urine alkalization improves the problems of pain and sleep in hypersensitive bladder syndrome. Int. J. Urol. 2014; 21: 512-7.
Jhang JF, Hsu YH, Jiang YH, Kuo HC. Elevated serum IgE may be associated with development of ketamine cystitis. J. Urol. 2014; 192: 1249-56.
Lee JD, Lee MH. Increased expression of hypoxia-inducible factor-1alpha and vascular endothelial growth factor associated with glomerulation formation in patients with interstitial cystitis. Urology. 2011; 78: e11-5.
Saban R. Angiogenic factors, bladder neuroplasticity and interstitial cystitis-new pathobiological insights. Transl. Androl. Urol. 2015; 4: 555-62.
Furuta A, Suzuki Y, Igarashi T et al. Angiogenesis in bladder tissues is strongly correlated with urinary frequency and bladder pain in patients with interstitial cystitis/bladder pain syndrome. Int. J. Urol. 2019; 26(Suppl 1): 35-40.
Peng CH, Jhang JF, Shie JH, Kuo HC. Down regulation of vascular endothelial growth factor is associated with decreased inflammation after intravesical onabotulinumtoxinA injections combined with hydrodistention for patients with interstitial cystitis-clinical results and immunohistochemistry analysis. Urology 2013; 82: e1-6.
Jhang JF, Ho HC, Jiang YH, Lee CL, Hsu YH, Kuo HC. Electron microscopic characteristics of interstitial cystitis/bladder pain syndrome and their association with clinical condition. PLoS One 2018; 13: e0198816.
Klingler CH. Glycosaminoglycans: how much do we know about their role in the bladder? Urologia 2016; 83(Suppl 1): 11-4.
Lee JD, Lee MH. Activation of extrinsic apoptotic pathway from bladder biopsy in patients with interstitial cystitis/painful bladder syndrome. Urology 2013; 82: e7-11.
Janssen DA, van Wijk XM, Jansen KC, van Kuppevelt TH, Heesakkers JP, Schalken JA. The distribution and function of chondroitin sulfate and other sulfated glycosaminoglycans in the human bladder and their contribution to the protective bladder barrier. J. Urol. 2013; 189: 336-42.
Liu HT, Shie JH, Chen SH, Wang YS, Kuo HC. Differences in mast cell infiltration, E-cadherin, and zonula occludens-1 expression between patients with overactive bladder and interstitial cystitis/bladder pain syndrome. Urology 2012; 80: e13-8.
Fuoco MB, Irvine-Bird K, Curtis Nickel J. Multiple sensitivity phenotype in interstitial cystitis/bladder pain syndrome. Can. Urol. Assoc. J. 2014; 8: E758-61.
Wada N, Ameda K, Furuno T, Okada H, Date I, Kakizaki H. Evaluation of prostaglandin E2 and E-series prostaglandin receptor in patients with interstitial cystitis. J. Urol. 2015; 193: 1987-93.
Liu HT, Tyagi P, Chancellor MB, Kuo HC. Urinary nerve growth factor level is increased in patients with interstitial cystitis/bladder pain syndrome and decreased in responders to treatment. BJU Int. 2009; 104: 1476-81.
Martinez-Martinez LA, Mora T, Vargas A, Fuentes-Iniestra M, Martinez-Lavin M. Sympathetic nervous system dysfunction in fibromyalgia, chronic fatigue syndrome, irritable bowel syndrome, and interstitial cystitis: a review of case-control studies. J. Clin. Rheumatol. 2014; 20: 146-50.
Charrua A, Pinto R, Taylor A et al. Can the adrenergic system be implicated in the pathophysiology of bladder pain syndrome/interstitial cystitis? A clinical and experimental study. Neurourol. Urodyn. 2015; 34: 489-96.
Williams DP, Chelimsky G, McCabe NP et al. Effects of chronic pelvic pain on heart rate variability in women. J. Urol. 2015; 194: 1289-94.
Warren JW, Morozov V, Howard FM et al. Before the onset of interstitial cystitis/bladder pain syndrome, the presence of multiple non-bladder syndromes is strongly associated with a history of multiple surgeries. J. Psychosom. Res. 2014; 76: 75-9.
Nickel JC, Tripp DA. Clinical and psychological parameters associated with pain pattern phenotypes in women with interstitial cystitis/bladder pain syndrome. J. Urol. 2015; 193: 138-44.
Fan YH, Lin AT, Lu SH, Chuang YC, Chen KK. Non-bladder conditions in female Taiwanese patients with interstitial cystitis/hypersensitive bladder syndrome. Int. J. Urol. 2014; 21: 805-9.
Chen IC, Lee MH, Lin HH, Wu SL, Chang KM, Lin HY. Somatoform disorder as a predictor of interstitial cystitis/bladder pain syndrome: evidence from a nested case-control study and a retrospective cohort study. Medicine 2017; 96: e6304.
Doiron RC, Tolls V, Irvine-Bird K, Kelly KL, Nickel JC. Clinical phenotyping does not differentiate Hunner lesion subtype of interstitial cystitis/bladder pain syndrome: a relook at the role of cystoscopy. J. Urol. 2016; 196: 1136-40.
Quaghebeur J, Wyndaele JJ. Comparison of questionnaires used for the evaluation of patients with chronic pelvic pain. Neurourol. Urodyn. 2013; 32: 1074-9.
Ackerman AL, Lai HH, Parameshwar PS, Eilber KS, Anger JT. Symptomatic overlap in overactive bladder and interstitial cystitis/bladder pain syndrome: development of a new algorithm. BJU Int. 2019; 123: 682-93.
Lee MH, Lin TL, Kuo HC, Chen YF. Clinical characteristic picture and impact of symptoms on quality of life of interstitial cystitis patients in Taiwan. Low. Urin. Tract Symptoms 2014; 1: 20-5.
Beckett MK, Elliott MN, Clemens JQ, Ewing B, Berry SH. Consequences of interstitial cystitis/bladder pain symptoms on women's work participation and income: results from a national household sample. J. Urol. 2014; 191: 83-8.
Kim SH, Oh SA, Oh SJ. Voiding diary might serve as a useful tool to understand differences between bladder pain syndrome/interstitial cystitis and overactive bladder. Int. J. Urol. 2014; 21: 179-83.
Charlanes A, Boudghene F, Chesnel C et al. Diffusion-weighted magnetic resonance imaging: a new tool for the diagnosis of bladder pain syndrome/interstitial cystitis. Urol. Int. 2019; 102: 109-12.
Jiang YH, Liu HT, Kuo HC. Decrease of urinary nerve growth factor but not brain-derived neurotrophic factor in patients with interstitial cystitis/bladder pain syndrome treated with hyaluronic acid. PLoS One 2014; 9: e91609.
Furuta A, Yamamoto T, Suzuki Y, Gotoh M, Egawa S, Yoshimura N. Comparison of inflammatory urine markers in patients with interstitial cystitis and overactive bladder. Int. Urogynecol. J. 2018; 29: 961-6.
Parker KS, Crowley JR, Stephens-Shields AJ et al. Urinary metabolomics identifies a molecular correlate of interstitial cystitis/bladder pain syndrome in a multidisciplinary approach to the study of chronic pelvic pain (MAPP) research network cohort. EBioMedicine 2016; 7: 167-74.
Offiah I, Didangelos A, Dawes J et al. The Expression of inflammatory mediators in bladder pain syndrome. Eur. Urol. 2016; 70: 283-90.
Magalhaes TF, Baracat EC, Doumouchtsis SK, Haddad JM. Biomarkers in the diagnosis and symptom assessment of patients with bladder pain syndrome: a systematic review. Int. Urogynecol. J. 2019; 30: 1785-94.
Yamada Y, Nomiya A, Niimi A et al. A survey on clinical practice of interstitial cystitis in Japan. Trans. Androl. Urol. 2015; 4: 486-90.
Lee MH, Wu HC, Tseng CM, Ko TL, Weng TJ, Chen YF. Health education and symptom flare management using a video-based m-health system for caring women with IC/BPS. Urology 2018; 119: 62-9.
Kanter G, Komesu YM, Qaedan F et al. Mindfulness-based stress reduction as a novel treatment for interstitial cystitis/bladder pain syndrome: a randomized controlled trial. Int. Urogynecol. J. 2016; 27: 1705-11.
Oh-Oka H. Clinical efficacy of 1-year intensive systematic dietary manipulation as complementary and alternative medicine therapies on female patients with interstitial cystitis/bladder pain syndrome. Urology 2017; 106: 50-4.
Pearce WA, Chen R, Jain N. Pigmentary maculopathy associated with chronic exposure to pentosan polysulfate sodium. Ophthalmology 2018; 125: 1793-802.
Jain N, Li AL, Yu Y, VanderBeek BL. Association of macular disease with long-term use of pentosan polysulfate sodium: findings from a US cohort. Br. J. Ophthalmol. 2019; https://doi.org/10.1136/bjophthalmol-2019-314765.
Ludwig CA, Vail D, Callaway NF, Pasricha MV, Moshfeghi DM. Pentosan polysulfate sodium exposure and drug-induced maculopathy in commercially insured patients in the United States. Ophthalmology 2019; https://doi.org/10.1016/j.ophtha.2019.10.036.
Crescenze IM, Tucky B, Li J, Moore C, Shoskes DA. Efficacy, side effects, and monitoring of oral cyclosporine in interstitial cystitis-bladder pain syndrome. Urology 2017; 107: 49-54.
Swamy S, Barcella W, De Iorio M et al. Recalcitrant chronic bladder pain and recurrent cystitis but negative urinalysis: what should we do? Int. Urogynecol. J. 2018; 29: 1035-43.
van Ophoven A, Hertle L. The dual serotonin and noradrenaline reuptake inhibitor duloxetine for the treatment of interstitial cystitis: results of an observational study. J. Urol. 2007; 177: 552-5.
Sasaki K, Smith CP, Chuang YC, Lee JY, Kim JC, Chancellor MB. Oral gabapentin (neurontin) treatment of refractory genitourinary tract pain. Tech. Urol. 2001; 7: 47-9.
Bouchelouche K, Nordling J, Hald T, Bouchelouche P. The cysteinyl leukotriene D4 receptor antagonist montelukast for the treatment of interstitial cystitis. J. Urol. 2001; 166: 1734-7.
Wammack R, Remzi M, Seitz C, Djavan B, Marberger M. Efficacy of oral doxepin and piroxicam treatment for interstitial cystitis. Eur. Urol. 2002; 41: 596-601.
Chen H, Wang F, Chen W et al. Efficacy of daily low-dose sildenafil for treating interstitial cystitis: results of a randomized, double-blind, placebo-controlled trial-treatment of interstitial cystitis/painful bladder syndrome with low-dose sildenafil. Urology 2014; 84: 51-6.
Bosch PC. A randomized, double-blind, placebo controlled trial of adalimumab for interstitial cystitis/bladder pain syndrome. J. Urol. 2014; 191: 77-82.
Bosch PC. A randomized, double-blind, placebo-controlled trial of certolizumab pegol in women with refractory interstitial cystitis/bladder pain syndrome. Eur. Urol. 2018; 74: 623-30.
Ueda Y, Tomoe H, Takahashi H et al. Interstitial cystitis associated with primary Sjogren's syndrome successfully treated with a combination of tacrolimus and corticosteroid: A case report and literature review. Mod. Rheumatol. 2016; 26: 445-9.
Tomoe H. In what type of interstitial cystitis/bladder pain syndrome is DMSO intravesical instillation therapy effective? Transl. Androl. Urol. 2015; 4: 600.
Iyer S, Lotsof E, Zhou Y et al. Which bladder instillations are more effective? DMSO vs. bupivacaine/heparin/triamcinolone: a retrospective study. Int. Urogynecol. J. 2017; 28: 1335-40.
Lim YN, Dwyer P, Murray C, Karmakar D, Rosamilia A, Thomas E. Long-term outcomes of intravesical dimethyl sulfoxide/heparin/hydrocortisone therapy for interstitial cystitis/bladder pain syndrome. Int. Urogynecol. J. 2017; 28: 1085-9.
Ozkidik M. Assessment of long-term intravesical hyaluronic acid, chondroitin sulfate and combination therapy for patients with bladder pain syndrome. Cent. European J. Urol. 2019; 72: 270-5.
Nickel JC, Hanno P, Kumar K, Thomas H. Second multicenter, randomized, double-blind, parallel-group evaluation of effectiveness and safety of intravesical sodium chondroitin sulfate compared with inactive vehicle control in subjects with interstitial cystitis/bladder pain syndrome. Urology 2012; 79: 1220-4.
Tutolo M, Ammirati E, Castagna G et al. A prospective randomized controlled multicentre trial comparing intravesical DMSO and chondroitin sulphate 2% for painful bladder syndrome/interstitial cystitis. Int. Braz. J. Urol. 2017; 43: 134-41.
Gulpinar O, Esen B, Kayis A, Gokce MI, Suer E. Clinical comparison of intravesical hyaluronic acid and chondroitin sulfate therapies in the treatment of bladder pain syndrome/interstitial cystitis. Neurourol. Urodyn. 2018; 37: 257-62.
Kuo HC, Jiang YH, Tsai YC, Kuo YC. Intravesical botulinum toxin-A injections reduce bladder pain of interstitial cystitis/bladder pain syndrome refractory to conventional treatment - A prospective, multicenter, randomized, double-blind, placebo-controlled clinical trial. Neurourol. Urodyn. 2015; 26: S22.
Akiyama Y, Nomiya A, Niimi A et al. Botulinum toxin type A injection for refractory interstitial cystitis: a randomized comparative study and predictors of treatment response. Int. J. Urol. 2015; 22: 835-41.
Lee CL, Kuo HC. Intravesical botulinum toxin A injections do not benefit patients with ulcer type interstitial cystitis. Pain Physician 2013; 16: 109-16.
Pinto RA, Costa D, Morgado A et al. Intratrigonal onabotulinumtoxinA improves bladder symptoms and quality of life in patients with bladder pain syndrome/interstitial cystitis: a pilot, single center, randomized, double-blind, placebo controlled trial. J. Urol. 2018; 199: 998-1003.
Rappaport YH, Zisman A, Jeshurun-Gutshtat M et al. Safety and feasibility of intravesical instillation of botulinum toxin-A in hydrogel-based slow-release delivery system in patients with interstitial cystitis-bladder pain syndrome: a pilot study. Urology 2018; 114: 60-5.
Rittenberg L, Morrissey D, El-Khawand D, Whitmore K. Kenalog injection into Hunner's lesions as a treatment for interstitial cystitis/bladder pain syndrome. Curr. Urol. 2017; 10: 154-6.
Funaro MG, King AN, Stern JNH, Moldwin RM, Bahlani S. Endoscopic injection of low dose triamcinolone: a simple, minimally invasive, and effective therapy for interstitial cystitis with Hunner lesions. Urology 2018; 118: 25-9.
Aihara K, Hirayama A, Tanaka N, Fujimoto K, Yoshida K, Hirao Y. Hydrodistension under local anesthesia for patients with suspected painful bladder syndrome/interstitial cystitis: safety, diagnostic potential and therapeutic efficacy. Int. J. Urol. 2009; 16: 947-52.
El-Hefnawy AS, Makharita MY, Abed A, Amr YM, Salah El-Badry M, Shaaban AA. Anesthetic bladder hydrodistention is superior to superior hypogastric plexus neurolysis in treatment of interstitial cystitis-bladder pain syndrome: a prospective randomized trial. Urology 2015; 85: 1039-44.
Niimi A, Nomiya A, Yamada Y et al. Hydrodistension with or without fulguration of hunner lesions for interstitial cystitis: long-term outcomes and prognostic predictors. Neurourol. Urodyn. 2016; 35: 965-9.
Zabihi N, Allee T, Maher MG et al. Bladder necrosis following hydrodistention in patients with interstitial cystitis. J. Urol. 2007; 177: 149-52.
Kirk PS, Santiago-Lastra Y, Qin Y, Stoffel JT, Clemens JQ, Cameron AP. The effects of cystoscopy and hydrodistention on symptoms and bladder capacity in interstitial cystitis/bladder pain syndrome. Neurourol. Urodyn. 2018; 37: 2002-7.
Walker SJ, Plair A, Hemal K et al. Bladder hydrodistention does not result in a significant change in bladder capacity for interstitial cystitis/bladder pain syndrome patients. Urology 2019; 132: 81-6.
Chennamsetty A, Khourdaji I, Goike J, Killinger KA, Girdler B, Peters KM. Electrosurgical management of Hunner ulcers in a referral center's interstitial cystitis population. Urology 2015; 85: 74-8.
Ko KJ, Chung H, Suh YS, Lee SW, Kim TH, Lee KS. Therapeutic effects of endoscopic ablation in patients with Hunner type interstitial cystitis. BJU Int. 2018; 121: 659-66.
Otsuka A, Suzuki T, Aki R et al. Clinical characteristics of self-reported nocturia in patients with interstitial cystitis, and effects of bladder hydrodistention (with fulguration of Hunner lesions) on nocturia. Low. Urin. Tract Symptoms 2019; 11: O141-6.
Lee SW, Kim WB, Lee KW et al. Transurethral resection alone vs resection combined with therapeutic hydrodistention as treatment for ulcerative interstitial cystitis: initial experience with propensity score matching studies. Urology 2017; 99: 62-8.
Tomoe H, Yamashita K. Does repeated hydrodistension with transurethral fulguration for interstitial cystitis with Hunner's lesion cause bladder contraction? Arab J. Urol. 2019; 17: 77-81.
Mateu Arrom L, Gutierrez Ruiz C, Mayordomo Ferrer O, Martinez Barea V, Palou Redorta J, Errando SC. Long-term follow-up after cystectomy for bladder pain syndrome: pain status, sexual function and quality of life. World J. Urol. 2019; 37: 1597-603.
Kim HJ, Lee JS, Cho WJ et al. Efficacy and safety of augmentation ileocystoplasty combined with supratrigonal cystectomy for the treatment of refractory bladder pain syndrome/interstitial cystitis with Hunner's lesion. Int. J. Urol. 2014; 21(Suppl 1): 69-73.
Yang TX, Luo DY, Li H, Wang KJ, Shen H. Is urethrectomy necessary during cystectomy in patients with interstitial cystitis or bladder pain syndrome? Urology. 2016; 97: 73-9.
Redmond EJ, Flood HD. The role of reconstructive surgery in patients with end-stage interstitial cystitis/bladder pain syndrome: is cystectomy necessary? Int. Urogynecol. J. 2017; 28: 1551-6.
Wang J, Chen Y, Chen J, Zhang G, Wu P. Sacral neuromodulation for refractory bladder pain syndrome/interstitial cystitis: a global systematic review and meta-analysis. Sci. Rep. 2017; 7: 11031.
Ragab MM, Tawfik AM, Abo El-enen M et al. Evaluation of percutaneous tibial nerve stimulation for treatment of refractory painful bladder syndrome. Urology 2015; 86: 707-11.
O'Hare PG 3rd, Hoffmann AR, Allen P, Gordon B, Salin L, Whitmore K. Interstitial cystitis patients' use and rating of complementary and alternative medicine therapies. Int. Urogynecol. J. 2013; 24: 977-82.
Sonmez MG, Kozanhan B. Complete response to acupuncture therapy in female patients with refractory interstitial cystitis/bladder pain syndrome. Ginekol. Pol. 2017; 88: 61-7.